Diagnostic criteria of cachexia and their assessment: Decreased muscle strength and fatigue

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 4, 2008, Pages 417-421

  Strasser, Florian ^a,b  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Anorexia; Cachexia; Cancer; Fatigue; Muscle strength

Indexed keywords

ADVANCED CANCER; CACHEXIA; CANCER PATIENT; HUMAN; MUSCLE ATROPHY; MUSCLE FATIGUE; MUSCLE MASS; MUSCLE STRENGTH; PHYSICAL ACTIVITY; PREDICTION; REVIEW; CHRONIC DISEASE; DIFFERENTIAL DIAGNOSIS; FATIGUE; PHYSIOLOGY;

CACHEXIA; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; FATIGUE; HUMANS; MUSCLE FATIGUE; MUSCLE STRENGTH;

EID: 54049124665     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3283025e27     Document Type: Review

References (46)

1. 4th Cachexia Conference, Tampa. December 6th-9th, 2007. www. cachexia.org [Accessed 25 February 2008].
2. Radbruch L, Strasser F, Elsner F, et al., the Research Steering Committee of the European Association for Palliative Care (EAPC). Fatigue in palliative care patients - an EAPC approach. Palliat Med 2008; 22:13-32.
3. Olson K, Turner AR, Courneya KS, et al. Possible links between behavioral and physiological indices of tiredness, fatigue, and exhaustion in advanced cancer. Support Care Cancer 2008; 16:241-249.
4. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13:63-74.
5. Stone P, Richards M, A'Hern R, Hardy J. Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. J Pain Symptom Manage 2001; 22:1007-1015.
6. Roscoe JA, Kaufman ME, Matteson-Rusby SE, et al. Cancer-related fatigue and sleep disorders. Oncologist 2007; 12 (Suppl 1):35-42.
7. Bruera E, Sweeney C, Willey J, et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med 2003; 17:659-663.
8. Brown DJ, McMillan DC, Milroy R. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer 2005; 103:377-382.
9. Yennurajalingam S, Bruera E. Palliative management of fatigue at the close of life: 'it feels like my body is just worn out'. JAMA 2007; 297: 295-304.
10. Strasser F, Palmer JL, Schover LR, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 2006; 107:2949-2957.
11. Vollmer-Conna U, Cameron B, Hadzi-Pavlovic D, et al., Dubbo Infective Outcomes Study Group. Postinfective fatigue syndrome is not associated with altered cytokine production. Clin Infect Dis 2007; 45:732-735.
12. Ryan JL, Carroll JK, Ryan EP, et al. Mechanisms of cancer-related fatigue. Oncologist 2007; 12 (Suppl 1):22-34.
13. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005; 104:788-793.
14. Del Fabbro E, Dalal S, Bruera E. Symptom control in palliative care-Part II: cachexia/anorexia and fatigue. J Palliat Med 2006; 9:409-421.
15. Bruera E, Sala R, Rico MA, et al. Effects of parenteral hydration in terminally ill cancer patients: a preliminary study. J Clin Oncol 2005; 23:2366-2371.
16. Walsh D, Rybicki L Symptom clustering in advanced cancer. Support Care Cancer 2006; 14:831-836.
17. Davis JM, Alderson NL, Welsh RS. Serotonin and central nervous system fatigue: nutritional considerations. Am J Clin Nutr 2000; 72 (2 Suppl) :573S-578S.
18. Meeusen R, Watson P, Hasegawa H, et al. Central fatigue: the serotonin hypothesis and beyond. Sports Med 2006; 36:881-909.
19. Davis MP, Ranganthan V, Walsh D, et al. Cancer related fatigue: central or peripheral? J Clin Oncol 2005; 23 (Suppl):8048. 2005 ASCO Annual Meeting Proceedings.
20. Hofman M, Ryan JL, Figueroa-Moseley CD, et al. Cancer-related fatigue: the scale of the problem. Oncologist 2007; 12 (Suppl 1):4 - 10.
21. Okuyama T, Tanaka K, Akechi T, et al. Fatigue in ambulatory patients with advanced lung cancer: prevalence, correlated factors, and screening. J Pain Symptom Manage 2001; 22:554-564.
22. Okuyama T, Akechi T, Shima Y, et al. Factors correlated with fatigue in terminally Ill cancer patients: a longitudinal study. J Pain Symptom Manage; 2008 [Epub ahead of print].
23. Jean-Pierre P, Figueroa-Moseley CD, Kohli S, et al. Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 2007; 12 (Suppl 1):11 -21.
24. Dworzak F, Ferrari P, Gavazzi C, et al. Effects of cachexia due to cancer on whole body and skeletal muscle protein turnover. Cancer 1998; 82: 42-48.
25. Attaix D, Ventadour S, Codran A, et al. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem 2005; 41:173-186.
26. Collins P, Bing C, McCulloch P, Williams G. Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br J Cancer 2002; 86:372-375.
27. Schmitt TL, Martignoni ME, Bachmann J, et al. Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia. J Mol Med 2007; 85:647-654.
28. Chelly MS, Chamari K, Verney J, Denis C. Comparison of muscle mechanical and histochemical properties between young and elderly subjects. Int J Sports Med 2006; 27:885-893.
29. Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 2006; 61:1059-1064.
30. Argiles JM, BusquetsS, Felipe A, Lopez-Soriano FJ. Muscle wasting in cancer and ageing: cachexia versus sarcopenia. Adv Gerontol 2006; 18:39-54.
31. Tisdale MJ. The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J Support Oncol 2005; 3:209-217.
32. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16:1639-1645.
33. Colson K, Doss DS, Swift R, et al. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs 2004; 8:473-480.
34. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97:1221-1224.
35. Romanus D, Archer L, Wang X, et al., for the Cancer and Leukemia Group B (CALGB). Does health-related quality of life (HRQL) improve for patients who respond to chemotherapy? Analysis of patients with advanced pancreas cancer (APC) receiving gemcitabine on cancer and leukemia Group B (CALGB) Study #80303. J Clin Oncol 2007; 25 (Suppl): 9008. 2007 ASCO Annual Meeting Proceedings.
36. Sencan O, BuyukcelikA, Yalcin B, et al. The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. Eur J Cancer Care (Engl) 2008; 17:26-32.
37. Gagnon D, Nadeau S, Gravel D, et al. Reliability and validity of static knee strength measurements obtained with a chair-fixed dynamometer in subjects with hip or knee arthroplasty. Arch Phys Med Rehabil 2005; 86:1998-2008.
38. Wang CY, Olson SL, Protas EJ. Test-retest strength reliability: hand-held dynamometry in community-dwelling elderly fallers. Arch Phys Med Rehabil 2002; 83:811-815.
39. O'Shea SD, Taylor NF, Paratz JD. Measuring muscle strength for people with chronic obstructive pulmonary disease: retest reliability of hand-held dynamometry. Arch Phys Med Rehabil 2007; 88:32-36.
40. Runge M, Rittweger J, RussoCR, et al. Is muscle power output a key factor in the age-related decline in physical performance? A comparison of muscle cross section, chair-rising test and jumping power. Clin Physiol Funct Imaging 2004; 24:335-340.
41. Dahele M, Skipworth RJ, Wall L, et al. Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. J Pain Symptom Manage 2007; 33:676-685.
42. Knobel H, Loge JH, Brenne E, et al. The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors. Palliat Med 2003; 17:664-672.
43. Jordhoy MS, Inger Ringdal G, Helbostad JL, et al. Assessing physical functioning: a systematic review of quality of life measures developed for use in palliative care. Palliat Med 2007; 21:673-682.
44. Fouladiun M, Korner U, Gunnebo L, et al. Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia. Clin Cancer Res 2007; 13:6379-6385.
45. Sloan JA, Berk L, Roscoe J, et al. National Cancer Institute. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol 2007; 25:5070-5077.
46. Brundage M, Osoba D, Bezjak A, et al., National Cancer Institute of Canada Clinical Trials Group. Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:5078-5081.